1. Home
  2. CYTK vs CAVA Comparison

CYTK vs CAVA Comparison

Compare CYTK & CAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.34

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo CAVA Group Inc.

CAVA

CAVA Group Inc.

HOLD

Current Price

$60.63

Market Cap

7.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
CAVA
Founded
1997
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.7B
IPO Year
2004
2023

Fundamental Metrics

Financial Performance
Metric
CYTK
CAVA
Price
$63.34
$60.63
Analyst Decision
Strong Buy
Buy
Analyst Count
16
20
Target Price
$84.81
$80.00
AVG Volume (30 Days)
1.8M
3.6M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
151.16
EPS
N/A
1.16
Revenue
$87,211,000.00
$1,132,074,000.00
Revenue This Year
$341.94
$24.00
Revenue Next Year
$75.44
$20.75
P/E Ratio
N/A
$52.28
Revenue Growth
2609.26
23.93
52 Week Low
$29.31
$43.41
52 Week High
$70.98
$144.49

Technical Indicators

Market Signals
Indicator
CYTK
CAVA
Relative Strength Index (RSI) 49.19 41.92
Support Level $62.13 $60.82
Resistance Level $65.88 $65.35
Average True Range (ATR) 2.59 2.76
MACD 0.07 -1.38
Stochastic Oscillator 54.84 0.69

Price Performance

Historical Comparison
CYTK
CAVA

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

Share on Social Networks: